Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

J. Monk, Bradley; W. Sill, Michael; A. Burger, Robert; J. Gray, Heidi; Buekers, Thomas; D. Roman, Lynda

doi:10.1200/jco.2008.18.9043

Public

Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Published in Journal of Clinical Oncology • Jan 13, 2009

Authors:

Bradley J. Monk

Michael W. Sill

Robert A. Burger

Abstract

PURPOSE: Vascular endothelial growth factor is a key promoter of tumor progression in cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal...

Subject

Medicine

Bevacizumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!